Abstract
Allogeneic stem cell transplantation (allo SCT) for multiple myeloma (MM) may exhibit graft versus myeloma effects (GVM) without contamination with tumor cells. It has been used as the only treatment method that may achieve the cure of myeloma. However, in comparative studies with autologous stem cell transplantation (auto SCT), the treatment-related mortality was high in patients who underwent allo SCT, not leading to an improvement in the prognosis; this procedure remains at the stage of experimental therapy. Recently, the introduction of proteasome inhibitors and immunomodulatory drugs has improved the results of MM treatment. A new therapeutic strategy for allo SCT involving a combination of these drugs should be developed.
